Unit 09, Office Tower
41st Floor, Room 4109 Convention Plaza 1 Harbour Road
Wan Chai
Hong Kong
852 2802 9886
https://www.sinobiopharm.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 25,806
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Ms. Y. Y. Tse | Executive Chairwoman of the Board | 5.48M | N/A | 1992 |
Ms. Cheung Ling Cheng | Executive Vice Chairwoman of the Board | 4.86M | N/A | 1964 |
Ms. Mingqin Li | Senior VP & Executive Director | 165.76k | N/A | 1959 |
Mr. Zhoushan Tian | Executive Director | 258.45k | N/A | 1964 |
Mr. Hsin Tse | Senior VP & Executive Director | 832.53k | N/A | 1970 |
Mr. Eric S. Y. Tse | CEO & Executive Director | 3.19M | N/A | 1996 |
Mr. Ping Tse | Founder & Senior Executive Vice Chairman | 5.79M | N/A | 1952 |
Ms. Chun Ling Li | Chief Financial Officer | N/A | N/A | 1972 |
Sean Chen | Chief Strategy Officer | N/A | N/A | N/A |
Orphanides George | Chief Scientific Advisor of invoX | N/A | N/A | N/A |
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines comprising Qingkeshu tablets, Focus V capsules, Annike injection, and Anyue capsules; liver disease medicines, including Tianqing ganmei injection and Runzhong dispersible tablets; and respiratory system medicines, such as Tianqing suchang suspension for inhalation and Tianyun for injection. It also provides surgery/analgesia medicines comprising Debaian cataplasms and Gaisanchun soft capsules; and cardio-cerebral vascular medicines, including Yilunping and Kaina tablets. In addition, the company is involved in the long term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Sino Biopharmaceutical Limited’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 4; Board: 2; Shareholder Rights: 7; Compensation: 9.